Pain and beyond: fatty acid amides and fatty acid amide hydrolase inhibitors in cardiovascular and metabolic diseases

S Pillarisetti, CW Alexander, I Khanna - Drug discovery today, 2009 - Elsevier
Fatty acid amide hydrolase (FAAH) is responsible for the hydrolysis of several important
endogenous fatty acid amides (FAAs), including anandamide, oleoylethanolamide and …

Latest advances in the discovery of fatty acid amide hydrolase inhibitors

T Bisogno, M Maccarrone - Expert opinion on drug discovery, 2013 - Taylor & Francis
Introduction: Fatty acid amide hydrolase (FAAH) is the major catabolic enzyme of the
endocannabinoid N-arachidonoylethanolamine (anandamide) that, with different degrees of …

Recent advances in the discovery and evaluation of fatty acid amide hydrolase inhibitors

H Deng - Expert Opinion on Drug Discovery, 2010 - Taylor & Francis
Importance of the field: Cannabis has been used for both medicinal and recreational
purposes since ancient times. Although cannabinoid-based medicines hold great promise in …

A perspective review on fatty acid amide hydrolase (FAAH) inhibitors as potential therapeutic agents

RKP Tripathi - European Journal of Medicinal Chemistry, 2020 - Elsevier
Fatty acid amide hydrolase (FAAH) is an important enzyme creditworthy of hydrolyzing
endocannabinoids and related-amidated signalling lipids, discovery of which has pioneered …

Fatty acid amide hydrolase inhibitors: a patent review (2009–2014)

A Lodola, R Castelli, M Mor, S Rivara - Expert Opinion on …, 2015 - Taylor & Francis
Introduction: Fatty acid amide hydrolase (FAAH) is a key enzyme responsible for the
degradation of the endocannabinoid anandamide. FAAH inactivation is emerging as a …

Development of potent inhibitors of fatty acid amide hydrolase useful for the treatment of neuropathic pain

M Brindisi, G Borrelli, S Brogi, A Grillo… - …, 2018 - Wiley Online Library
The unique role of fatty acid amide hydrolase (FAAH) in terminating endocannabinoid (EC)
signaling supports its relevance as a therapeutic target. Inhibition of EC metabolizing …

Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and …

K Ahn, SE Smith, MB Liimatta, D Beidler… - … of Pharmacology and …, 2011 - ASPET
The endogenous cannabinoid (endocannabinoid) anandamide is principally degraded by
the integral membrane enzyme fatty acid amide hydrolase (FAAH). Pharmacological …

Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders

K Ahn, DS Johnson, BF Cravatt - Expert opinion on drug discovery, 2009 - Taylor & Francis
Background: Fatty acid amide hydrolase (FAAH) is an integral membrane enzyme that
hydrolyzes the endocannabinoid anandamide and related amidated signaling lipids …

Fatty acid amide hydrolase inhibitors-progress and potential

IK Khanna, CW Alexander - CNS & Neurological Disorders …, 2011 - ingentaconnect.com
Fatty acid amide hydrolase (FAAH) is responsible for hydrolysis of endocannabinoid,
anandamide (AEA), and N-acyl ethanolamines such as palmitoylethanolamine (PEA) and N …

Discovery of potent inhibitors of human and mouse fatty acid amide hydrolases

S Butini, M Brindisi, S Gemma, P Minetti… - Journal of Medicinal …, 2012 - ACS Publications
Fatty acid amide hydrolase (FAAH, EC 3.5. 1.99) is the main enzyme catabolizing
endocannabinoid fatty acid amides. FAAH inactivation promotes beneficial effects upon pain …